Bioxytran, Inc.
BIXT
$0.109
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.47% | -20.48% | -23.15% | 55.80% | 135.18% |
| Depreciation & Amortization | -20.41% | -4.82% | 62.96% | 102.22% | 206.25% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.82% | -41.47% | -23.31% | 31.01% | 85.77% |
| Operating Income | 48.82% | 41.47% | 23.31% | -31.01% | -85.77% |
| Income Before Tax | 30.87% | 52.07% | 37.38% | -3.56% | -68.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.87% | 52.07% | 37.38% | -3.56% | -68.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -81.19% | -70.54% | -70.65% | -57.46% | -59.65% |
| Net Income | 30.01% | 51.69% | 36.43% | -6.72% | -78.02% |
| EBIT | 48.82% | 41.47% | 23.31% | -31.01% | -85.77% |
| EBITDA | 48.89% | 41.55% | 23.44% | -30.89% | -85.58% |
| EPS Basic | 8.05% | 52.44% | 46.75% | 11.51% | -52.04% |
| Normalized Basic EPS | -5.18% | 31.68% | 41.92% | 3.95% | -64.96% |
| EPS Diluted | 8.05% | 52.44% | 46.75% | 11.51% | -52.04% |
| Normalized Diluted EPS | -5.18% | 31.68% | 41.92% | 3.95% | -64.96% |
| Average Basic Shares Outstanding | -15.88% | 4.30% | 19.91% | 26.84% | 21.57% |
| Average Diluted Shares Outstanding | -15.88% | 4.30% | 19.91% | 26.84% | 21.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |